Evidence map›Paper›PMID 40741098›Full record

ArticleWorld journal of gastroenterology2025

Correlation between radiomic features of Crohn's disease and secondary loss of response to infliximab.

Shuai Li, Chao Zhu, Li Tong, Xiao-Min Zheng, Chang Rong, Yan-Kun Gao, Dong-Cun Yuan, Xing-Wang Wu

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Objective Endoscopic Assessment for Prediction of Secondary Loss of Response of Biologics in Crohn's Disease.Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society · 2026
    Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Shuai LiDepartment of Radiology, The First Affiliated Hospital of Anhui Medical University, Hefei 230031, Anhui Province, China.
Chao ZhuDepartment of Radiology, Yijishan Hospital of Wanan Medical University, Wuhu 241000, Anhui Province, China.
Li TongDepartment of Radiology, The First Affiliated Hospital of Anhui Medical University, Hefei 230031, Anhui Province, China.
Xiao-Min ZhengDepartment of Radiology, The First Affiliated Hospital of Anhui Medical University, Hefei 230031, Anhui Province, China.
Chang RongDepartment of Radiology, The First Affiliated Hospital of Anhui Medical University, Hefei 230031, Anhui Province, China.
Yan-Kun GaoDepartment of Radiology, The First Affiliated Hospital of Anhui Medical University, Hefei 230031, Anhui Province, China.
Dong-Cun YuanDepartment of Radiology, Anhui Woman and Children's Medical Center, Hefei 230031, Anhui Province, China.
Xing-Wang WuDepartment of Radiology, The First Affiliated Hospital of Anhui Medical University, Hefei 230031, Anhui Province, China. duobi2004@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCrohn's disease (CD) is a type of inflammatory bowel disease, with chronic and progressive characteristics. Infliximab (IFX) can rapidly relieve CD-related symptoms and promote mucosal healing. However, some patients may occur secondary loss of response (SLOR) during the maintenance treatment, leading to the recurrence or progression of CD. The current IFX efficacy prediction models for CD have limited applicability to SLOR. Radiomics, as a non-invasive technique, is expected to serve as a more accurate tool for predicting the risk of SLOR.

aimTo develop a radiomics-based model via integrative analysis of intestinal wall and creeping fat to predict SLOR in CD.

methodsWe retrospectively analyzed clinical and imaging data from 220 CD patients in two centers. Univariate and multivariate analyses were used to screen out clinically independent predictors of SLOR. Radiomics features of the intestinal wall and creeping fat were extracted and fused together for analysis. Univariate and least absolute shrinkage and selection operator analyses were used to select the most valuable radiomics features to calculate Radscore and develop radiomics predictive model. A combined predictive model was developed based on the Radscore and clinically independent predictors through multivariate logistic regression analysis. Area under the receiver operating characteristic curve (AUC), calibration curve and the decision curve analysis were used to verify model performance.

resultsWhite blood cell count, disease duration and Harvey-Bradshaw Index were identified as clinically independent predictors of SLOR to develop the clinical model. Fifteen most valuable radiomics features were selected to develop the radiomics model. Compared with the clinical and radiomics models, the combined model achieved the best prediction performance, with AUCs were 0.871 (95%CI: 0.814-0.929) in the training cohort and 0.854 (95%CI: 0.759-0.949) in the validation cohort.

conclusionThe combined model that integrates intestinal wall and creeping fat analysis is valuable for predicting the SLOR of IFX in CD.

Indexed as

Crohn DiseaseGastrointestinal AgentsInfliximabAdultDisease ProgressionFemaleHumansIntestinal MucosaMaleMiddle AgedPredictive Value of TestsRadiomicsRecurrenceRetrospective StudiesROC CurveTomography, X-Ray ComputedGastrointestinal AgentsInfliximabComputed tomography enterographyCreeping fatCrohn's diseaseInfliximabRadiomics

Identifiers

PMID40741098
PMCPMC12305135

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.